Skip to Content

Exjade Approval History

FDA Approved: Yes (First approved November 2, 2005)
Brand name: Exjade
Generic name: deferasirox
Dosage form: Dispersible Tablets
Company: Novartis
Treatment for: Hemosiderosis, Iron Overload

Exjade (deferasirox) is a once-daily oral iron chelator approved for the treatment of chronic iron overload due to blood transfusions, and non-transfusion-dependent thalassemia.

Development History and FDA Approval Process for Exjade

DateArticle
Jan 23, 2013Approval FDA Approves Exjade to Remove Excess Iron in Patients with Genetic Blood Disorder
Nov  2, 2005Approval Exjade Novartis - Treatment for Chronic Iron Overload Due to Blood Transfusions
Sep 29, 2005FDA Advisory Committee Votes Unanimously to Recommend Approval of Exjade for Once-Daily Oral Treatment of Chronic Iron Overload Due to Blood Transfusions
Jun 22, 2005FDA Grants Priority Review for Exjade for the Treatment of Chronic Iron Overload Due to Blood Transfusions
May  3, 2005Novartis Files Exjade New Drug Applications for Treatment of Chronic Iron Overload Due to Blood Transfusions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide